New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
08:02 EDTLGNDLigand announces presentation of data from Phase 1 study
Ligand Pharmaceuticals announced that data from a Phase 1 study of the selective estrogen receptor modulator lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago. The presentation provided data from a first-in-human clinical study of lasofoxifene that was performed by Pfizer and recently analyzed by Ligand demonstrating the potent and prolonged effect of a single dose to increase circulating testosterone and gonadotropin levels in healthy young men. Highlights of the presentation include: In an investigator-blinded, randomized, placebo-controlled, single-ascending dose study involving 36 healthy male volunteers, lasofoxifene was well-absorbed after oral administration with peak plasma concentrations reached approximately 6 to 9 hours post-dose and a long elimination half-life of approximately 106 hours; There were no serious adverse events and no clinically significant changes in safety laboratory, vital signs or ECG assessments; Single oral doses of lasofoxifene of 1, 3, 10, 30 and 100 mg increased levels of testosterone; doses of 30 and 100 mg increased levels of T by more than 80%; Levels of luteinizing hormone and follicle-stimulating hormone were also elevated with single oral doses of 30 and 100 mg; Levels of T, LH and FSH peaked between 3 and 7 days post-dose and elevations induced by higher doses were maintained through at least 28 days; T levels plateaued at the high normal range of 30-40 nmol/L between 7 and 28 days post-dose regardless of lasofoxifene dose or LH levels.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
10:01 EDTLGNDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Bacterin (BONE) initiated with a Buy at H.C. Wainwright... Cognizant (CTSH) initiated with a Buy at Argus... Comerica (CMA) initiated with a Neutral at UBS... Delphi Automotive (DLPH) initiated with a Neutral at Northcoast... Dunkin' Brands (DNKN) initiated with a Neutral at UBS... Easterly Government Properties (DEA) initiated with an Outperform at RBC Capital... Fifth Third (FITB) initiated with a Buy at UBS... Hilton (HLT) initiated with an Outperform at RBC Capital... KeyCorp (KEY) initiated with a Neutral at UBS... Ligand (LGND) initiated with a Buy at CRT Capital... M&T Bank (MTB) initiated with a Neutral at UBS... MPLX (MPLX) initiated with a Hold at Evercore ISI... Marriott (MAR) initiated with an Outperform at RBC Capital... Nexvet Biopharma (NVET) initiated with an Outperform at JMP Securities... Regions Financial (RF) initiated with a Neutral at UBS... Shell Midstream (SHLX) initiated with a Buy at Evercore ISI... Starwood (HOT) initiated with a Sector Perform at RBC Capital... Sunoco Logistics (SXL) initiated with a Hold at Evercore ISI... Syneron Medical (ELOS) initiated with a Buy at Brean Capital... Tesoro Logistics (TLLP) initiated with a Buy at Evercore ISI... Valero Energy Partners (VLP) initiated with a Buy at Evercore ISI... Vista Outdoor (VSTO) initiated with a Buy at CRT Capital... Zions Bancorp (ZION) initiated with a Sell at UBS.
08:23 EDTLGNDLigand initiated with a Buy at CRT Capital
Target $102.
March 2, 2015
09:19 EDTLGNDLigand data should establish superiority of Kyprolis, says Roth Capital
Subscribe for More Information
February 19, 2015
14:52 EDTLGNDLigand management to meet with Craig-Hallum
Meetings to be held in Minneapolis on February 23 and in Chicago on February 24 hosted by Craig-Hallum.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use